Reference
National Institute for Health and Care Excellence (NICE). NICE draft guidance does not recommend tucatinib for advanced breast cancer. Internet Document : 26 Oct 2021. Available from: URL: https://www.nice.org.uk/news/article/nice-draft-guidance-does-not-recommend-tucatinib-for-advanced-breast-cancer
Rights and permissions
About this article
Cite this article
UK's NICE does not recommend tucatinib for HER2-positive metastatic breast cancer. PharmacoEcon Outcomes News 891, 37 (2021). https://doi.org/10.1007/s40274-021-08195-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08195-6